利用尿液肿瘤DNA检测与监测膀胱癌
本研究开发了utDNA CAPP-Seq高通量测序方法,用于检测尿液肿瘤DNA,并应用于67名健康成人和118例早期膀胱癌患者。治疗前检测灵敏度为93%(肿瘤突变信息引导)和84%(盲法),特异性96%至100%;监测中91%复发患者可检出utDNA,92%早于临床进展。uCAPP-Seq优于UroVysion(P=0.02)及细胞学与膀胱镜联合(P≤0.006)。
要点
- uCAPP-Seq可高灵敏度、高特异性检测早期膀胱癌患者尿液肿瘤DNA。
- 监测中91%最终复发患者可检出utDNA,92%早于临床进展。
- uCAPP-Seq优于UroVysion(P=0.02)及细胞学联合膀胱镜(P≤0.006)。
核心结论
- uCAPP-Seq是早期检测和监测膀胱癌的有前景的方法。
研究设计与样本
- 研究纳入67名健康成人和118例早期膀胱癌患者,尿液采集于治疗前或监测期间。
- 采用靶向高通量测序方法utDNA CAPP-Seq检测尿液肿瘤DNA。
主要发现
- 每例膀胱癌患者中位检出6个突变,PLEKHS1启动子突变频率为46%。
- 治疗前utDNA检出率:肿瘤突变信息引导法为93%,盲法为84%,特异性96%至100%。
- 监测中91%最终复发患者检出utDNA,92%病例中utDNA检测早于临床进展。
- uCAPP-Seq检出细胞学检测到的100%膀胱癌病例及细胞学漏检的82%病例。
关键数值与推荐
- uCAPP-Seq优于常用辅助检测UroVysion(P=0.02)。
- uCAPP-Seq优于细胞学与膀胱镜联合(P≤0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current regimens for the detection and surveillance of bladder cancer are invasive and have suboptimal sensitivity. Here, we present a novel high-throughput sequencing (HTS) method for detection of urine tumor DNA (utDNA) called utDNA CAPP-Seq (uCAPP-Seq) and apply it to 67 healthy adults and 118 patients with early-stage bladder cancer who had urine collected either prior to treatment or during surveillance. Using this targeted sequencing approach, we detected a median of 6 mutations per patient with bladder cancer and observed surprisingly frequent mutations of the PLEKHS1 promoter (46%), suggesting these mutations represent a useful biomarker for detection of bladder cancer. We detected utDNA pretreatment in 93% of cases using a tumor mutation-informed approach and in 84% when blinded to tumor mutation status, with 96% to 100% specificity. In the surveillance setting, we detected utDNA in 91% of patients who ultimately recurred, with utDNA detection preceding clinical progression in 92% of cases. uCAPP-Seq outperformed a commonly used ancillary test (UroVysion, P = 0.02) and cytology and cystoscopy combined (P ≤ 0.006), detecting 100% of bladder cancer cases detected by cytology and 82% that cytology missed. Our results indicate that uCAPP-Seq is a promising approach for early detection and surveillance of bladder cancer. SIGNIFICANCE: This study shows that utDNA can be detected using HTS with high sensitivity and specificity in patients with early-stage bladder cancer and during post-treatment surveillance, significantly outperforming standard diagnostic modalities and facilitating noninvasive detection, genotyping, and monitoring.This article is highlighted in the In This Issue feature, p. 453.
引用
- Dudley JC, Schroers-Martin J, Lazzareschi DV, et al. Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discov. 2018. PMID: 30578357. doi:10.1158/2159-8290.CD-18-0825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。